Oncolytics Biotech (ONCY) Institutional Ownership $0.53 -0.02 (-3.82%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Oncolytics Biotech (NASDAQ:ONCY)CurrentInstitutional OwnershipPercentage6.82%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$258.06KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$20.96K Get ONCY Insider Trade Alerts Want to know when executives and insiders are buying or selling Oncolytics Biotech stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ONCY Institutional Buying and Selling by Quarter Remove Ads Oncolytics Biotech Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/12/2025Geode Capital Management LLC66,939$61K0.0%+59.6%0.084% 2/12/2025National Bank of Canada FI64,479$60K0.0%+199.6%0.081% 2/11/2025Virtu Financial LLC98,452$90K0.0%N/A0.123% 1/24/2025Vantage Point Financial LLC29,744$27K0.0%N/A0.037% 1/8/2025International Assets Investment Management LLC200,400$186K0.0%+15.0%0.259% 10/22/2024International Assets Investment Management LLC174,331$152K0.0%-12.1%0.228% 5/20/2024Virtu Financial LLC51,889$55K0.0%N/A0.068% 1/24/2024International Assets Investment Management LLC269,699$364K0.0%+33.9%0.362% 1/12/2024Advisor Resource Council100,000$135K0.0%N/A0.134% 1/11/2024Ausdal Financial Partners Inc.30,000$40K0.0%+50.0%0.041% Get the Latest News and Ratings for ONCY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. 11/8/2023Ausdal Financial Partners Inc.20,000$44K0.0%N/A0.027% 10/13/2023Brave Asset Management Inc.25,000$55K0.0%+150.0%0.035% 10/10/2023International Assets Investment Management LLC201,453$449K0.0%+3.3%0.278% 10/4/2023International Assets Investment Management LLC201,453$449K0.0%+3.3%0.278% 8/23/2023Headinvest LLC11,534$30K0.0%N/A0.016% 8/2/2023Bank of Montreal Can32,380$85K0.0%N/A0.049% 7/24/2023Brave Asset Management Inc.10,000$26K0.0%N/A0.015% 7/20/2023International Assets Investment Management LLC194,963$507K0.1%+3.4%0.297% 2/7/2023Lynwood Capital Management Inc.25,000$41K0.0%N/A0.041% 1/24/2023International Assets Investment Management LLC169,111$609K0.1%-6.9%0.276% 1/20/2023Newman Dignan & Sheerar Inc.18,915$31K0.0%+46.5%0.031% 8/11/2022Toronto Dominion Bank35,362$34K0.0%N/A0.061% 7/27/2022Advisor Resource Council100,000$101K0.0%N/A0.173% 2/14/2022Long Focus Capital Management LLC40,000$56K0.0%N/A0.073% 2/11/2022Advisor Resource Council100,000$139K0.0%N/A0.182% 11/12/2021Renaissance Technologies LLC209,900$439K0.0%+812.6%0.382% 10/28/2021International Assets Investment Management LLC170,576$357K0.1%+5.4%0.310% 10/7/2021Newman Dignan & Sheerar Inc.12,915$27K0.0%N/A0.023% 9/17/2021Virtu Financial LLC35,425$98K0.0%N/A0.064% 8/19/2021Advisor Resource Council101,000$280K0.0%N/A0.184% 8/13/2021Renaissance Technologies LLC23,000$64K0.0%N/A0.042% 8/12/2021JPMorgan Chase & Co.150,673$919K0.0%+167.7%0.274% 8/12/2021Bank of Montreal Can16,460$46K0.0%+40.1%0.030% 7/31/2021Brave Asset Management Inc.20,000$55K0.0%+100.0%0.036% 5/21/2021Citadel Advisors LLC49,378$188K0.0%N/A0.093% 5/19/2021Chiron Capital Management LLC10,000$38K0.0%N/A0.019% 5/19/2021Squarepoint Ops LLC11,650$44K0.0%N/A0.022% 5/18/2021Citadel Advisors LLC49,378$188K0.0%N/A0.093% 5/17/2021Royal Bank of Canada27,381$105K0.0%-23.0%0.052% 5/17/2021Goldman Sachs Group Inc.10,300$39K0.0%N/A0.019% Trump’s Secret Weapon (Ad)Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.Get Your FREE Presidential Transition Guide Today5/12/2021Geode Capital Management LLC24,545$92K0.0%+51.4%0.046% 5/12/2021JPMorgan Chase & Co.56,283$214K0.0%N/A0.107% 5/11/2021Toronto Dominion Bank22,465$85K0.0%+190.5%0.043% 5/11/2021Banque Cantonale Vaudoise11,268$42K0.0%+723.7%0.021% 4/26/2021Brave Asset Management Inc.10,000$38K0.0%N/A0.019% 4/19/2021International Assets Investment Management LLC277,852$885K0.1%+130.1%0.533% 2/24/2021Virtu Financial LLC19,587$47K0.0%N/A0.047% 2/10/2021Renaissance Technologies LLC174,220$415K0.0%+1,284.3%0.418% (Data available from 1/1/2016 forward)Remove Ads ONCY Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ONCY shares? During the previous two years, 10 institutional investors and hedge funds held shares of Oncolytics Biotech. The most heavily invested institutionals were International Assets Investment Management LLC ($186K), Advisor Resource Council ($135K), Virtu Financial LLC ($90K), Bank of Montreal Can ($85K), Geode Capital Management LLC ($61K), National Bank of Canada FI ($60K), and Brave Asset Management Inc. ($55K).Learn more on ONCY's institutional investors. What percentage of Oncolytics Biotech stock is owned by institutional investors? 6.82% of Oncolytics Biotech stock is owned by institutional investors. Learn more on ONCY's institutional investor holdings. Which institutional investors have been buying Oncolytics Biotech stock? Of the 10 institutional investors that purchased Oncolytics Biotech stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Virtu Financial LLC ($150.34K), International Assets Investment Management LLC ($113.64K), Advisor Resource Council ($100K), National Bank of Canada FI ($42.96K), Bank of Montreal Can ($32.38K), Ausdal Financial Partners Inc. ($30K), and Vantage Point Financial LLC ($29.74K). How much institutional buying is happening at Oncolytics Biotech? Institutional investors have bought a total of 560,586 shares in the last 24 months. This purchase volume represents approximately $759.95K in transactions. Which Oncolytics Biotech major shareholders have been selling company stock? The following institutional investors have sold Oncolytics Biotech stock in the last 24 months: International Assets Investment Management LLC ($24.07K). How much institutional selling is happening at Oncolytics Biotech? Institutional investors have sold a total of 24,069 shares in the last 24 months. This volume of shares sold represents approximately $20.96K in transactions. Related Companies Inhibrx Institutional Ownership AC Immune Institutional Ownership DiaMedica Therapeutics Institutional Ownership biote Institutional Ownership SOPHiA GENETICS Institutional Ownership Neurogene Institutional Ownership Protalix BioTherapeutics Institutional Ownership RAPT Therapeutics Institutional Ownership Contineum Therapeutics Institutional Ownership Checkpoint Therapeutics Institutional Ownership This page (NASDAQ:ONCY) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
